Table 2 The mean change scores (post-treatment and follow-up scores adjusted for baseline^a) for the clinical outcome measures, including the number of participants (N), means, and standard deviations (SD) for the antidepressant and no antidepressant groups, and the estimated between-groups effect size (Cohen’s d with 95% confidence intervals)

 BMI

16

0.03

0.72

10

0.16

0.36

0.22 (− 0.58 to 1.01)

 EDE-Q Global

16

− 0.34

0.68

10

− 0.09

0.56

0.40 (−0.41 to 1.19)

 EDE-Q Restraint

16

−0.18

0.73

10

0.14

0.67

0.45 (−0.36 to 1.24)

 EDE-Q Eating Concern

16

−0.43

0.83

10

−0.12

0.84

0.37 (−0.43 to 1.16)

 EDE-Q Shape Concern

16

−0.45

0.74

10

−0.10

1.11

0.38 (−0.42 to 1.18)

 EDE-Q Weight Concern

16

−0.33

0.83

10

−0.30

0.94

0.03 (−0.76 to 0.82)

 DASS-21 Total

16

−9.00

22.14

10

−16.2

19.31

−0.34 (−1.13 to 0.46)

 DASS-21 Depression

16

−1.25

8.61

10

−4.80

8.34

−0.42 (−1.21 to 0.39)

 DASS-21 Anxiety

16

−3.63

8.86

10

−4.20

4.76

−0.08 (− 0.87 to 0.72)

 BMI

15

0.27

1.17

10

0.06

0.89

−0.20 (−1.00 to 0.91)

 EDE-Q Global

15

−0.88

0.85

10

−0.03

0.62

1.10 (0.23 to 1.96)

 EDE-Q Restraint

15

−0.75

1.29

10

0.18

0.68

0.85 (0.001 to 1.67)

 EDE-Q Eating Concern

15

−0.67

1.06

10

0.06

0.95

0.71 (−0.12 to 1.53)

 EDE-Q Shape Concern

15

−1.06

0.83

10

−0.09

0.83

1.17 (0.29 to 2.03)

 EDE-Q Weight Concern

15

−1.04

1.01

10

−0.28

0.67

0.85 (0.006 to 1.68)

 DASS-21 Total

15

−17.33

23.80

10

−14.4

18.40

0.13 (−0.69 to 0.93)

 DASS-21 Depression

15

−8.13

10.43

10

−4.20

8.24

0.41 (−0.41 to 1.21)

 DASS-21 Anxiety

15

−4.40

7.57

10

−3.00

7.13

0.19 (−0.62 to 0.99)